Last in the series of videos from RSNA 2013, the focus is on developing technology to further improve patient experience.
Innovation is key to providing affordable healthcare for the world’s population
Read more
Join GE Healthcare and pharmaphorum for a tweetchat on neurological disorders
Read more
Timelapse video shows creation of GE Healthcare's booth at RSNA 2013
Read more
Mission to elevate patient care education standards
Read more
Last in the series of videos from RSNA 2013, the focus is on developing technology to further improve patient experience.
One area where GE Healthcare pioneers in is breast cancer care. Through continued investment and development new technology continues to be introduced to meet the needs of patients and clinicians around the world.
Yesterday, Jeff Immelt hosted an event at the GE Healthcare booth at RSNA 2013 to highlight two of the latest innovations from GE.
GE Healthcare today announced the U.S. Food and Drug Administration (FDA) approval of Vizamyl™ (Flutemetamol F18 injection), a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline.
Got any comments?
Please let us know what you think of this site.
